Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19

Documenti analoghi

• Detection of SARS-CoV-2 infection in asymptomatic populations using the DiaSorin molecular Simplexa and Roche Cobas EUA assays
  di: Antonara, Stella, et al.
  Pubblicazione: (2022)
• A Tale of Two Countries: DiaSorin Molecular’s Rapid Response to the COVID-19 Pandemic
  di: Michelle M. Tabb, et al.
  Pubblicazione: (2022-04-01)
• One swab, two tests: Validation of dual SARS-CoV-2 testing on the Abbott ID NOW™
  di: Burnes, Laura E, et al.
  Pubblicazione: (2021)
• Analytical and clinical performance of the fully-automated LIAISONXL calprotectin immunoassay from DiaSorin in IBD patients
  di: Vicente-Steijn, R., et al.
  Pubblicazione: (2020)
• 418. Comparison of the Abbott SARS-CoV-2 IgG and DiaSorin LIASON SARS-CoV-2 S1/S2 IgG Antibody Assays
  di: Schaack, Grace A, et al.
  Pubblicazione: (2020)